Pei-Pei Kung

This inventor holds 16 USPTO granted patents and 15 published patent applications, plus 9 CIPO patents and 10 EPO patents. Top assignees: Pfizer Corporation, Agouron Pharmaceuticals, Inc., Ctxt Pty Limited. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pei-Pei Kung. Retrieved from https://idiyas.com/inventor/pei-pei-kung

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 15)

% Patents Active = 87.5

CIPO Patents = 9 (Patent Applications = 2)

EPO Patents = 10 (Patent Applications = 14)

Average Co-Inventor Count = 6.1

ph-index = 6

Forward Citations = 151(Granted Patents)

Company Filing History:

Agouron Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12545669 - Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives (2026-02-10),

2. 12371425 - Benzisoxazole sulfonamide derivatives (2025-07-29),

3. 11529344 - EZH2 inhibitor combination therapies (2022-12-20),

4. 11492346 - Benzisoxazole sulfonamide derivatives (2022-11-08),

5. 10676471 - Cycloalkyl-linked diheterocycle derivatives (2020-06-09),

6. 10570121 - Substituted dihydroisoquinolinone compounds (2020-02-25),

7. 10246433 - Aryl and heteroaryl fused lactams (2019-04-02),

8. 10125130 - Cycloalkyl-linked diheterocycle derivatives (2018-11-13),

9. 9481666 - Substituted dihydroisoquinolinone compounds (2016-11-01),

10. 9040515 - Aryl and heteroaryl fused lactams (2015-05-26),

11. 8785632 - Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors (2014-07-22),

12. 8106197 - Aminoheteroaryl compounds as protein kinase inhibitors (2012-01-31),

13. 8080556 - 2-amino pyrimidine compounds as potent HSP-90 inhibitors (2011-12-20),

14. 7858643 - Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors (2010-12-28),

15. 7465842 - Enantioselective biotransformation for preparation of protein tyrosine kinase inhibitor intermediates (2008-12-16),

Title: Pei-Pei Kung: Innovator in Pharmaceutical Chemistry

Introduction

Pei-Pei Kung is a prominent inventor based in San Diego, California, known for her significant contributions to pharmaceutical chemistry. With a total of 15 patents to her name, she has made remarkable advancements in the field, particularly in the development of compounds for treating abnormal cell growth, including cancer.

Latest Patents

Among her latest patents, Pei-Pei Kung has developed benzisoxazole sulfonamide derivatives. This invention relates to compounds of a specific formula, which are useful in treating abnormal cell growth in patients. The novel derivatives are designed to be effective against cancer and include pharmaceutical compositions and methods for their use. Additionally, she has worked on EZH2 inhibitor combination therapies, which involve combining an EZH2 inhibitor with a chemotherapeutic agent. This invention also includes associated pharmaceutical compositions and methods of treatment.

Career Highlights

Throughout her career, Pei-Pei Kung has worked with notable companies such as Pfizer Corporation and Agouron Pharmaceuticals, Inc. Her work has significantly impacted the pharmaceutical industry, particularly in cancer research and treatment.

Collaborations

Pei-Pei Kung has collaborated with esteemed colleagues, including Scott Channing Sutton and Jerry Jialun Meng. These collaborations have further enhanced her research and development efforts in the pharmaceutical field.

Conclusion

Pei-Pei Kung's innovative work in pharmaceutical chemistry has led to the development of important treatments for cancer and other diseases. Her contributions continue to influence the industry and improve patient outcomes.

Profile summary based on public USPTO records.